Jazz Pharmaceuticals
JAZZ
437 hedge funds and large institutions have $8.69B invested in Jazz Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 131 increasing their positions, 173 reducing their positions, and 30 closing their positions.
170% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 30
46% more call options, than puts
Call options by funds: $115M | Put options by funds: $78.8M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
12% more funds holding
Funds holding: 389 → 437 (+48)
12% more capital invested
Capital invested by funds: $7.77B → $8.69B (+$927M)
3.72% less ownership
Funds ownership: 98.32% → 94.6% (-3.7%)
24% less repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 173
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$44.7M |
| 2 |
Goldman Sachs
New York
|
+$35.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$32.2M |
| 4 |
Jennison Associates
New York
|
+$29.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$25.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$78.9M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
-$67.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.5M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$43.3M |
| 5 |
Renaissance Technologies
New York
|
-$35.1M |
JAZZ Hedge Fund Activity: Q4 2020 in Review
437 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2020, worth a combined $8.69B — up 12% from $7.77B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new JAZZ positions and 30 closed out — a net gain of 51 holders — while 131 added to existing stakes and 173 trimmed.
The largest buyer was BlackRock, adding an estimated $44.7M. The largest seller was Nuveen, cutting an estimated $78.9M.
- 437 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2020, up from 389 in Q3 2020.
- Funds reported $8.69B of Jazz Pharmaceuticals stock for Q4 2020, up 12% quarter-over-quarter.
- 81 funds opened new Jazz Pharmaceuticals positions in Q4 2020 and 30 closed out, a net change of +51 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2020 was BlackRock, an estimated $44.7M added.
- The largest Jazz Pharmaceuticals seller in Q4 2020 was Nuveen, an estimated $78.9M sold.
Based on aggregated 13F filings for Q4 2020.